How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?

Overview

Journal Obes Surg

Date 2015 Oct 16

PMID 26467690

Citations 5

Authors

Rute M Cerqueira

Manuel R Correia

Helder Vilar

M Conceicao Manso

Affiliations

Soon will be listed here.

Abstract

Aims And Methods: Our aim was to assess, in obese patients undergoing Roux-en Y gastric bypass surgery, the quadruple concomitant HP eradication rates at first line treatment as proposed by the Maastricht IV consensus in areas of high clarithromycin resistance rates-proton pump inhibitor bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid, and metronidazole 500 mg bid. This is a single center prospective study over a 3-year period. Endoscopy and HP assessment (by histology or C13 urea breath) were performed at baseline, and post treatment HP status was assessed by C13 urea breath test 4-6 weeks after the end of therapy.

Results: The study cohort consisted of 600 adult obese HP positive patients [19 % male/81 % female, age 40.7 (±10.4) years] consecutively scheduled for HP concomitant therapy. HP was eradicated in 416 patients [69.3 % (95% CI 65.5-72.9 %)] and the eradication was independent of gender, age, endoscopic diagnosis, and smoking status (p > 0.05).

Conclusions: Two weeks quadruple concomitant therapy did not achieve Maastricht recommended first line acceptable HP eradication rates (at least 80 %) in obese Portuguese patients undergoing GB.

Citing Articles

Effects of Preoperative Quadruple Therapy for Helicobacter pylori on Bariatric Surgery Metabolic Outcomes.

Goday A, Bagan A, Casajoana A, Serra C, Pera M, Villatoro M Obes Surg. 2024; 34(4):1196-1206.

PMID: 38400943 PMC: 11026217. DOI: 10.1007/s11695-024-07091-x.

Bismuth-Based Therapy: The New Therapy for Obese Patients Undergoing Gastric Bypass Surgery?.

Maria C, Rodriguez C, Ines P, Helder V, Mafalda S, Ricardo V Obes Surg. 2023; 34(1):123-127.

PMID: 37914885 DOI: 10.1007/s11695-023-06549-8.

Pellicano R Obes Surg. 2017; 28(2):553-554.

PMID: 29197049 DOI: 10.1007/s11695-017-3038-2.

Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery.

Cerqueira R, Correia M, Vilar H, Manso M Obes Surg. 2017; 28(3):743-747.

PMID: 29076008 DOI: 10.1007/s11695-017-2915-z.

GASTRIC AND JEJUNAL HISTOPATHOLOGICAL CHANGES IN PATIENTS UNDERGOING BARIATRIC SURGERY.

Rodrigues R, Almeida E, Camilo S, Terra-Junior J, Guimaraes L, Duque A Arq Bras Cir Dig. 2016; 29Suppl 1(Suppl 1):35-38.

PMID: 27683773 PMC: 5064251. DOI: 10.1590/0102-6720201600S10010.

References

Malfertheiner P, Megraud F, OMorain C, Bazzoli F, El-Omar E, Graham D . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2006; 56(6):772-81. PMC: 1954853. DOI: 10.1136/gut.2006.101634. View

Yamamoto H, Sekine Y, Sato Y, Higashizawa T, Miyata T, Iino S . Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc. 2001; 53(2):216-20. DOI: 10.1067/mge.2001.112181. View

Cerqueira R, Correia M, Fernandes C, Vilar H, Manso M . Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery. Obes Surg. 2012; 23(2):145-9. DOI: 10.1007/s11695-012-0747-4. View

Orlando G, Pilone V, Vitiello A, Gervasi R, Lerose M, Silecchia G . Gastric cancer following bariatric surgery: a review. Surg Laparosc Endosc Percutan Tech. 2014; 24(5):400-5. DOI: 10.1097/SLE.0000000000000050. View

Gill K, McKinney J, Stark M, Bouras E . Investigation of the excluded stomach after Roux-en-Y gastric bypass: the role of percutaneous endoscopy. World J Gastroenterol. 2008; 14(12):1946-8. PMC: 2700407. DOI: 10.3748/wjg.14.1946. View

Malfertheiner P, Megraud F, OMorain C, Atherton J, Axon A, Bazzoli F . Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5):646-64. DOI: 10.1136/gutjnl-2012-302084. View

Megraud F . H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53(9):1374-84. PMC: 1774187. DOI: 10.1136/gut.2003.022111. View

Silecchia G, Catalano C, Gentileschi P, Elmore U, Restuccia A, Gagner M . Virtual gastroduodenoscopy: a new look at the bypassed stomach and duodenum after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2002; 12(1):39-48. DOI: 10.1381/096089202321144568. View

Cerqueira R, Manso M, Correia M, Fernandes C, Vilar H, Nora M . Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days?. Obes Surg. 2010; 21(9):1377-81. DOI: 10.1007/s11695-010-0254-4. View

10.

Essa A, Kramer J, Graham D, Treiber G . Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14(2):109-18. PMC: 2840655. DOI: 10.1111/j.1523-5378.2009.00671.x. View

11.

Gisbert J, Calvet X . Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012; 5:23-34. PMC: 3308633. DOI: 10.2147/CEG.S25419. View

12.

Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N . Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes (Lond). 2007; 31(4):569-77. DOI: 10.1038/sj.ijo.0803560. View

13.

Toros A, Ince A, Kesici B, Saglam M, Polat Z, Uygun A . A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. Helicobacter. 2011; 16(3):225-8. DOI: 10.1111/j.1523-5378.2011.00823.x. View

14.

Graham D, Fischbach L . Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59(8):1143-53. DOI: 10.1136/gut.2009.192757. View

15.

Zhu R, Chen K, Zheng Y, Zhang H, Wang J, Xia Y . Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 2014; 20(47):18013-21. PMC: 4273153. DOI: 10.3748/wjg.v20.i47.18013. View

16.

Mathers C, Loncar D . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. PMC: 1664601. DOI: 10.1371/journal.pmed.0030442. View

17.

Wu D, Hsu P, Wu J, Opekun A, Kuo C, Wu I . Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2009; 8(1):36-41.e1. PMC: 2838430. DOI: 10.1016/j.cgh.2009.09.030. View

18.

Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Duenas-Sadornil C, Hernandez-Alonso M . Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter. 2012; 17(4):269-76. DOI: 10.1111/j.1523-5378.2012.00947.x. View

19.

Greenberg E, Anderson G, Morgan D, Torres J, Chey W, Bravo L . 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011; 378(9790):507-14. PMC: 3313469. DOI: 10.1016/S0140-6736(11)60825-8. View

20.

Anderson M, Gan S, Fanelli R, Baron T, Banerjee S, Cash B . Role of endoscopy in the bariatric surgery patient. Gastrointest Endosc. 2008; 68(1):1-10. DOI: 10.1016/j.gie.2008.01.028. View